Payer Policy

Blue Shield of California Prior Authorization Guide 2026: Phone, Fax, Form 61-211 & Appeals

How to get specialty drugs approved by Blue Shield of California in 2026: where to submit PA, California's 72-hour drug PA rule and Form 61-211, step therapy exceptions, grievances, and DMHC Independent Medical Review.

RxCheckUp Clinical Team · 2026-11-01 · 13 min read

Blue Shield of California vs. Anthem Blue Cross: Confirm the Plan First

California is the only state with two Blue plans. Blue Shield of California is an independent nonprofit insurer; Anthem Blue Cross of California is part of Elevance Health. They have different formularies, medical policies, portals, and appeal addresses. Sending a Blue Shield request to Anthem (or the reverse) is a common and avoidable cause of delay, so check the logo and payer ID on the member card before you start.

Within Blue Shield, the product line decides which rules apply. Fully insured commercial HMO and PPO plans are regulated by the California Department of Managed Health Care (DMHC) or the Department of Insurance. Self-funded employer plans that Blue Shield administers follow federal ERISA rules. Blue Shield 65 Plus and other Medicare Advantage plans follow CMS rules. Blue Shield of California Promise Health Plan serves Medi-Cal members, and since 2022 most outpatient Medi-Cal pharmacy claims have been handled by the state's Medi-Cal Rx program rather than by the health plan.

Pharmacy Benefit vs. Medical Benefit

Self-administered drugs filled at a retail or specialty pharmacy — GLP-1 receptor agonists, oral oncology agents, and self-injected biologics such as Humira, Dupixent, Skyrizi, and Cosentyx — are reviewed on the pharmacy benefit. Drugs given in a clinic or infusion center and billed with HCPCS J-codes — Ocrevus, Entyvio IV, Keytruda, Tysabri — are reviewed on the medical benefit against Blue Shield Medical Policies.

Blue Shield restructured its pharmacy benefit beginning in 2024, moving from a single traditional PBM to several specialized vendors. The pharmacy PA channel can therefore differ by plan and year. Check the member's ID card and the current Blue Shield provider pharmacy pages for the right channel before sending a request.

✓ Pharmacy benefit: electronic PA through the EHR (CoverMyMeds or Surescripts) or California Form 61-211 by fax
✓ Medical benefit: submit through the Blue Shield Provider Connection portal (blueshieldca.com/provider)
✓ Medicare Advantage: Part B drugs through the medical PA process; Part D drugs through the Part D coverage determination process
✓ Medi-Cal (Promise): outpatient pharmacy drugs generally go to Medi-Cal Rx; physician-administered drugs go to the plan

Blue Shield of California Contact Information

Contact details change and vary by product, so confirm against the member ID card and the Blue Shield provider site before submitting. Commonly used provider channels:

✓ Provider customer service and PA phone: 1-800-541-6652
✓ Prior authorization fax: 1-888-397-4498
✓ Appeals and grievances mailing address: Blue Shield of California, PO Box 272540, Chico, CA 95927
✓ Provider portal: Provider Connection at blueshieldca.com/provider
✓ Medical Policies: blueshieldca.com/provider/authorizations/medical-policy

California's Drug Prior Authorization Rules: Form 61-211 and the 72-Hour Clock

California law sets one of the strongest prescription drug PA frameworks in the country for state-regulated plans. Health plans must accept the state's standard Prescription Drug Prior Authorization or Step Therapy Exception Request Form (Form 61-211), and they must respond within 72 hours for non-urgent requests and 24 hours for exigent requests. If the plan does not respond in time, the request is deemed approved (Health and Safety Code §1367.241 and Insurance Code §10123.191).

Use the form even when you also send a letter. It shows that the request is complete and starts the statutory clock. Keep the fax confirmation: if the deadline passes without a decision, that record supports a deemed-approval argument.

These timelines apply to DMHC- and CDI-regulated plans. Self-funded ERISA plans and Medicare Advantage plans follow their own federal timelines.

Step-by-Step: Submitting a Blue Shield of California Prior Authorization

Step 1 — Find the governing policy. Look up the Blue Shield Medical Policy (medical benefit) or the plan's drug criteria (pharmacy benefit) and note the policy name or number. Citing it shows the reviewer you are answering their own criteria.

Step 2 — Build a criteria checklist. Diagnosis and ICD-10 code, severity measures, required prior therapies, labs or biomarkers, prescriber specialty, and dosing or quantity limits. Most denials happen because one criterion was skipped.

Step 3 — Document prior therapies precisely. List each drug with dose, start and stop dates, and the specific reason it was stopped. "Failed methotrexate" is weak; "methotrexate 20 mg weekly 02/2025–08/2025, stopped for CDAI 31 and ALT 3x ULN" is strong.

Step 4 — Attach a Letter of Medical Necessity. Lead with the request, cite the policy, address each criterion in order, and reference FDA labeling and specialty society guidelines.

Step 5 — Mark exigent requests. If a delay could seriously jeopardize the patient's health or ability to regain function, or the patient is on a current course of treatment with a non-formulary drug, request exigent review to start the 24-hour clock.

California Step Therapy Exceptions

California requires state-regulated plans to grant a step therapy exception when the prescriber submits justification and supporting clinical documentation (Health and Safety Code §1367.244). Plans also cannot require a patient to repeat a step therapy drug they already tried under a prior plan. Name the exception scenario in your request rather than leaving the reviewer to infer it.

✓ The required drug is contraindicated or likely to cause an adverse reaction for this patient
✓ The required drug is expected to be ineffective based on the patient's known clinical characteristics
✓ The patient already tried the required drug, or a drug with the same mechanism, and it failed or was not tolerated — including under a previous plan
✓ The patient is stable on the prescribed drug, and switching would risk destabilizing a controlled condition
✓ The required drug is not in the patient's best interest because it would create a barrier to adherence or daily functioning

Typical Blue Shield Criteria by Drug Class

Exact criteria depend on the plan and policy version, but common patterns include:

✓ Rheumatoid arthritis biologics and JAK inhibitors: conventional DMARD trial (usually methotrexate) and TB screening; preferred biologics or biosimilars before non-preferred agents
✓ Psoriasis biologics: documented BSA/PASI plus phototherapy or a conventional systemic agent first
✓ Atopic dermatitis: topical corticosteroid and calcineurin inhibitor trials with baseline EASI/IGA before Dupixent, Adbry, or Ebglyss
✓ GLP-1 receptor agonists: type 2 diabetes diagnosis and A1c for Ozempic and Mounjaro; Wegovy and Zepbound coverage depends on whether the group includes an anti-obesity benefit
✓ Oral oncology: biomarker report, line of therapy, and NCCN category of evidence
✓ Infused biologics: site-of-care review that may steer stable patients from hospital outpatient departments to home or office infusion

Top Reasons Blue Shield of California Denies Prior Authorization

Denials usually come down to a short list of fixable issues:

✓ Medical Policy criteria not addressed point by point
✓ Step therapy not completed and no exception scenario documented
✓ Non-preferred drug when a preferred biosimilar or alternative is on formulary
✓ Missing severity scores, labs, or biomarker results
✓ Request sent to the wrong benefit or the wrong Blue plan (Anthem Blue Cross instead of Blue Shield)
✓ Site-of-care restriction for infused drugs

How to Appeal a Blue Shield of California Denial

Read the denial letter for the exact reason and policy cited. If the decision was clinical, request a peer-to-peer discussion with the Blue Shield medical director; many denials are reversed once missing context is explained.

For DMHC-regulated plans, the member (or the prescriber on the member's behalf) files a grievance, generally within 180 days of the denial. Plans must resolve standard grievances within 30 days and urgent grievances within 72 hours. Include a rebuttal letter that quotes the denial reason and answers it directly, plus new supporting documentation.

If the grievance is denied — or after 30 days without a resolution, or right away for urgent cases — the member can apply to the DMHC for an Independent Medical Review (IMR). IMR is free to the member, decided by independent physicians, and binding on the plan. Members generally have six months from the plan's final decision to apply. The DMHC Help Center (1-888-466-2219, dmhc.ca.gov) handles applications. CDI-regulated policies have a parallel IMR process through the California Department of Insurance.

For Blue Shield Medicare Advantage and Part D plans, CMS timelines apply: Part D coverage determinations are decided within 72 hours (24 hours expedited), and redeterminations must be requested within 65 days of the denial notice.

Checklist: A Blue Shield of California PA Packet That Gets Approved

Before you submit, confirm the packet includes:

✓ Correct Blue plan (Blue Shield, not Anthem Blue Cross) and correct benefit channel
✓ Completed Form 61-211 for pharmacy requests on state-regulated plans, with the fax confirmation saved
✓ Blue Shield Medical Policy or drug criteria referenced in the letter
✓ ICD-10 code with full specificity and baseline severity scores
✓ Dated prior therapy history with objective reasons for discontinuation
✓ Required labs, screenings, and biomarker reports attached
✓ Named step therapy exception scenario under California law, where relevant
✓ Specific request: drug, dose, frequency, route, and duration

How RxCheckUp Helps With Blue Shield of California Prior Authorizations

RxCheckUp maps each request to the relevant Blue Shield of California criteria, flags missing documentation before submission, and generates a Letter of Medical Necessity that addresses each criterion in order with linked clinical evidence. For denials, it drafts a targeted grievance that quotes the denial reason and cites California step therapy and Independent Medical Review rights.